Trigeminal neuralgia

DikpalSingh1 248 views 29 slides Jul 13, 2018
Slide 1
Slide 1 of 29
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29

About This Presentation

Trigeminal Neuralgia, consized


Slide Content

Trigeminal neuralgia Dr Dikpal

ANATOMY

History 2 nd Century : Aretaeus , account of TN 1756 : Nicolas Andre, Tic Douloureux 1773: Forthergill , Clinical Features 1820: Charles Bell, Cause 1932: Walter Dandy, MVD 1970 : NAP were gold std 1967: Janetta reintroduced MVD

Clinical Features Site: Divisional, Unilateral Character: sharp, shooting, unbearable, arresting Timing: seconds- min. , no after pain Provoking: light touch Relieving: Sleep, Drugs Diurnal : More in morning

Burchiel`s Classification TN type 1 : >50 % episodic pain (Spontaneous) TN type 2 : > 50% constant pain TG neuropathic pain: unintentional trauma TG Deafferentation pain: intentional deafferention Symptomatic TGN: MS / Tumour Post Herpetic Neuralgia: HZ outbreak Atypical Facial Pain: somatoform pain disorder

Pathophysiology Pulsatile mechanical trauma Obersteiner - Redlich Zone Ectopic action potential Spontaneous / triggered after discharge Cross excitation from neighbouring afferent fibre Elongation of cisternal arteries with age : disease of elderly

Differential Diagnosis Dental MS Atypical TN TM joint Pathology Postherpetic Neuralgia Cluster Headache

Investigation Clinical diagnosis Support Diagnosis: MRI Structural lesions ( cavernoma , schwanomma , meningioma ) Vascular loops White Matter Lesions CISS (constructive interference in steady state ) BERA / PTA

Treatment

Medical Carbamazepine : (CBC, Sr Na, LFT, ) Oxcarbamazepine Baclofen Gabapentin Eptoin

Surgery Failure / partial relief with medication after 1 year > 3000 tablets of single drug Drugs toxicity Patient preference

Percutaneous ablative Elderly MS Pontine infarction White matter lesion w/o MS Previously failed MVD

Radiofrequency Ablation Alternating electric field, heat Hartel technique Supine , head extended 30 degree Lesion : 75-80 degree C for 90 sec End point : hypoaesthesia BEST among percutaneous

Glycerol Rhizotomy 20 G , 3.5 Inch Spinal Needle Sitting position Selective neurolysis : floating glycerol technique Contact time : atleast 1 hour

Balloon Compression Supine with head extended 15 degree 14 G blunt obturator No. 4 Fogarty Intraluminal pressure 1200 – 1500 mmHg (1-1.5atm) {tissue: 650-950 mmHg} Compression time less than 2 mins

Post operative management Corneal sensation Jaw opening exercises, soft diet Meningitis (Glycerol vs infective) COMPLICATION Dysesthesia (RF) Corneal hypoesthesia (glycerol) Masseter weakness (balloon) Stroke , hemorrhage, pseudomeningocele , CN weakness

Radiosurgery MOA: Axonal degeneration by radiation : presumed Arteriolar thickening of vessel in contact More effective as initial modality Target : Root entry zone Dose : 70-90 Gy Recurrence : delivery at anterior to previous site Cumulative dose < 140 Gy Approx 4-6 weeks for pain relief High recurrence

MVD Indication Contraindication : unfit, elderly , MS

Steps Lateral position Retro sigmoid craniotomy Cerebellum retracted inferiorly and medially Preserve veins , arteries Inspect V nerve Teflon / muscle / dacron / gelfoam No compression : gentle manipulation / section at antero inferior aspect

Complication Mortality < 0.5% Facial weakness, hearing loss Recurrence female venous compression failure of immediate pain relief > 8 yrs symptoms

Special cases Multiple sclerosis Balloon compression is the best Recurrent Cases MVD recurrence Glycerol recurrence SRS recurrence

Thanks
Tags